{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:00:57Z","timestamp":1792807257106,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32 DA007294"],"award-info":[{"award-number":["T32 DA007294"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K24 DA022412"],"award-info":[{"award-number":["K24 DA022412"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32 DA007294"],"award-info":[{"award-number":["T32 DA007294"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40263-019-00637-z","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T16:36:04Z","timestamp":1557160564000},"page":"567-580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":200,"title":["Buprenorphine Treatment for Opioid Use Disorder: An Overview"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2941-8895","authenticated-orcid":false,"given":"Matisyahu","family":"Shulman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Wai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"issue":"12","key":"637_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","volume":"5","author":"L Degenhardt","year":"2018","unstructured":"Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987\u20131012.","journal-title":"Lancet Psychiatry."},{"key":"637_CR2","unstructured":"Center for Behavioral Health Statistics and Quality (CBHSQ). 2015 National Survey on Drug Use and Health: detailed tables. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2016."},{"issue":"5","key":"637_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1001\/archpsyc.58.5.503","volume":"58","author":"YI Hser","year":"2001","unstructured":"Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001;58(5):503\u20138.","journal-title":"Arch Gen Psychiatry"},{"key":"637_CR4","unstructured":"World Health Organization. Department of Mental Health, Substance Abuse, World Health Organization, International Narcotics Control Board, United Nations Office on Drugs, Crime. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009."},{"issue":"2","key":"637_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","volume":"23","author":"HS Connery","year":"2015","unstructured":"Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63\u201375.","journal-title":"Harv Rev Psychiatry."},{"issue":"6","key":"637_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/00952990.2018.1461876","volume":"44","author":"R Walker","year":"2018","unstructured":"Walker R, Logan TK, Chipley QT, Miller J. Characteristics and experiences of buprenorphine-naloxone use among polysubstance users. Am J Drug Alcohol Abuse. 2018;44(6):595\u2013603.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"637_CR7","unstructured":"Williams A, Nunes E, Olfson M. To battle the opioid overdose epidemic, deploy the \u2018cascade of care\u2019 model. Health affairs blog. 2017. \n                    https:\/\/www.healthaffairs.org\/do\/10.1377\/hblog20170313.059163\/full\/\n                    \n                  . Accessed 20 Nov 2018."},{"key":"637_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1201\/b14312-4","volume-title":"Methadone matters: evolving community methadone treatment of opiate addiction","author":"A Preston","year":"2003","unstructured":"Preston A, Bennett G. The history of methadone and methadone prescribing. In: Strang J, Tober G, editors. Methadone matters: evolving community methadone treatment of opiate addiction. Taylor and Francis Group: London; 2003. p. 13\u201320."},{"issue":"2","key":"637_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1056-8719(00)00043-5","volume":"42","author":"MJ Garrido","year":"1999","unstructured":"Garrido MJ, Troc\u00f3niz IF. Methadone: a review of its pharmacokinetic\/pharmacodynamic properties. J Pharm Toxicol Methods. 1999;42(2):61\u20136.","journal-title":"J Pharm Toxicol Methods."},{"issue":"2","key":"637_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0740-5472(02)00259-3","volume":"23","author":"MJ Kreek","year":"2002","unstructured":"Kreek MJ, Vocci FJ. History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat. 2002;23(2):93\u2013105.","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"637_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","volume":"193","author":"VP Dole","year":"1965","unstructured":"Dole VP, Nyswander MA. Medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA. 1965;193(8):646\u201350.","journal-title":"JAMA"},{"issue":"4","key":"637_CR12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/archinte.1966.00290160004002","volume":"118","author":"VP Dole","year":"1966","unstructured":"Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade. Arch Intern Med. 1966;118(4):304\u20139.","journal-title":"Arch Intern Med"},{"key":"637_CR13","first-page":"224","volume":"81","author":"J Ball","year":"1988","unstructured":"Ball J, Corty E, Bond H, Myers C, Tommasello A. The reduction of intravenous heroin use, non-opiate abuse and crime during methadone maintenance treatment: further findings. NIDA Res Monogr. 1988;81:224\u201330.","journal-title":"NIDA Res Monogr"},{"issue":"4","key":"637_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1046\/j.1360-0443.1998.9345157.x","volume":"93","author":"LA Marsch","year":"1998","unstructured":"Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93(4):515\u201332.","journal-title":"Addiction"},{"issue":"2","key":"637_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/10826089609045806","volume":"31","author":"JR Caplehorn","year":"1996","unstructured":"Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts\u2019 risk of fatal heroin overdose. Subst Use Misuse. 1996;31(2):177\u201396.","journal-title":"Subst Use Misuse"},{"issue":"6","key":"637_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/jat\/20.6.369","volume":"20","author":"JJ Kuhlman Jr","year":"1996","unstructured":"Kuhlman JJ Jr, Lalani S, Magluilo J Jr, Levine B, Darwin WD, Johnson RE, et al. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol. 1996;20(6):369\u201378.","journal-title":"J Anal Toxicol"},{"issue":"3\u20134","key":"637_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/0376-8716(85)90067-5","volume":"14","author":"JW Lewis","year":"1985","unstructured":"Lewis JW. Buprenorphine. Drug Alcohol Depend. 1985;14(3\u20134):363\u201372.","journal-title":"Drug Alcohol Depend"},{"key":"637_CR18","first-page":"CD002207","volume":"2","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"637_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/BF02287379","volume":"31","author":"D Deck","year":"2004","unstructured":"Deck D, Carlson MJ. Access to publicly funded methadone maintenance treatment in two western states. J Behav Health Serv Res. 2004;31(2):164\u201377.","journal-title":"J Behav Health Serv Res."},{"key":"637_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-018-4801-3","author":"SL Calcaterra","year":"2019","unstructured":"Calcaterra SL, Bach P, Chadi A, Chadi N, Kimmel SD, Morford KL, et al. Methadone matters: what the United States can learn from the global effort to treat opioid addiction. J Gen Intern Med. 2019. \n                    https:\/\/doi.org\/10.1007\/s11606-018-4801-3\n                    \n                  \n                           (Epub ahead of print).","journal-title":"J Gen Intern Med."},{"issue":"5","key":"637_CR21","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11920-007-0046-2","volume":"9","author":"M Fatseas","year":"2007","unstructured":"Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep. 2007;9(5):358\u201364.","journal-title":"Curr Psychiatry Rep."},{"issue":"2 Suppl.","key":"637_CR22","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0376-8716(03)00055-3","volume":"70","author":"JH Jaffe","year":"2003","unstructured":"Jaffe JH, O\u2019Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003;70(2 Suppl.):S3\u201311.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"637_CR23","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","volume":"105","author":"CM Jones","year":"2015","unstructured":"Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55\u201363.","journal-title":"Am J Public Health"},{"issue":"4","key":"637_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1300\/J069v25n04_09","volume":"25","author":"W Kissin","year":"2006","unstructured":"Kissin W, McLeod C, Sonnefeld J, Stanton AJ. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25(4):91\u2013103.","journal-title":"J Addict Dis"},{"issue":"2","key":"637_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1370\/afm.1595","volume":"12","author":"E Hutchinson","year":"2014","unstructured":"Hutchinson E, Catlin M, Andrilla CH, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128\u201333.","journal-title":"Ann Fam Med."},{"issue":"3","key":"637_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.drugpo.2009.10.005","volume":"21","author":"M Schaub","year":"2010","unstructured":"Schaub M, Chtenguelov V, Subata E, Weiler G, Uchtenhagen A. Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine. Int J Drug Policy. 2010;21(3):229\u201333.","journal-title":"Int J Drug Policy."},{"issue":"6","key":"637_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.7196\/SAMJ.2017.v107i6.12140","volume":"107","author":"G Michie","year":"2017","unstructured":"Michie G, Hoosain S, Macharia M, Weich L. Report on the first government-funded opioid substitution programme for heroin users in the Western Cape Province, South Africa. S Afr Med J. 2017;107(6):539\u201342.","journal-title":"S Afr Med J."},{"issue":"1","key":"637_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1749-6632.2011.06352.x","volume":"1248","author":"ND Campbell","year":"2012","unstructured":"Campbell ND, Lovell AM. The history of the development of buprenorphine as an addiction therapeutic. Ann N Y Acad Sci. 2012;1248(1):124\u201339.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"637_CR29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","volume":"35","author":"DR Jasinski","year":"1978","unstructured":"Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry. 1978;35(4):501\u201316.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"637_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.9740\/mhc.2018.07.175","volume":"8","author":"AM Peckham","year":"2018","unstructured":"Peckham AM, De La Cruz A, Dufresne RL. Kappa opioid receptor antagonism: are opioids the answer for treatment resistant depression? Ment Health Clin. 2018;8(4):175\u201383.","journal-title":"Ment Health Clin."},{"issue":"6","key":"637_CR31","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/npp.2014.330","volume":"40","author":"E Ehrich","year":"2015","unstructured":"Ehrich E, Turncliff R, Du Y, Leigh-Pemberton R, Fernandez E, Jones R, et al. Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacology. 2015;40(6):1448\u201355.","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl. 4","key":"637_CR32","doi-asserted-by":"publisher","first-page":"S197","DOI":"10.1086\/508184","volume":"43","author":"MP Carrieri","year":"2006","unstructured":"Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. Clin Infect Dis. 2006;43(Suppl. 4):S197\u2013215.","journal-title":"Clin Infect Dis."},{"key":"637_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2471\/BLT.12.111815","volume":"91","author":"R Rao","year":"2013","unstructured":"Rao R, Agrawal A, Kishore K, Ambekar A. Delivery models of opioid agonist maintenance treatment in South Asia: a good beginning. Bull World Health Organ. 2013;91:150\u20133.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"637_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/14659891.2018.1489906","volume":"24","author":"A ElKashef","year":"2018","unstructured":"ElKashef A, Alzayani S, Shawky M, Al Abri M, Littlewood R, Qassem T, et al. Recommendations to improve opioid use disorder outcomes in countries of the Middle East. J Subst Use. 2018;24(1):4\u20137.","journal-title":"J Subst Use."},{"issue":"31","key":"637_CR35","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.drugpo.2016.02.013","volume":"1","author":"H Himmich","year":"2016","unstructured":"Himmich H, Madani N. The state of harm reduction in the Middle East and North Africa: a focus on Iran and Morocco. Int J Drug Policy. 2016;1(31):184\u20139.","journal-title":"Int J Drug Policy."},{"issue":"31","key":"637_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.drugpo.2016.04.008","volume":"1","author":"H Himmich","year":"2016","unstructured":"Himmich H, Kazatchkine MD, Stimson GV. Drug policy and human rights in the Middle East and North Africa: harm reduction, legal environment and public health. Int J Drug Policy. 2016;1(31):4\u20135.","journal-title":"Int J Drug Policy."},{"key":"#cr-split#-637_CR37.1","unstructured":"SOSFS 2004:8. Socialstyrelsens f\u00f6reskrifter och allm\u00e4nna r\u00e5d om l\u00e4kemedelsassisterad behandling vid opioidberoende (The National Board of Health and Welfare's regulations and general advice about drug-assisted treatment with opioids). In: Gemensamma f\u00f6rfattningssamlingen avseende h\u00e4lso- och sjukv\u00e5rd, socialtj\u00e4nst, l\u00e4kemedel, folkh\u00e4lsa m.m. (Common constitutional collection regarding healthcare, social services, medicines, public health, etc.). Sweden: \u00d6dman, Par, National Board of Health and Welfare"},{"key":"#cr-split#-637_CR37.2","unstructured":"2016.   https:\/\/www.socialstyrelsen.se\/Lists\/Artikelkatalog\/Attachments\/20053\/2016-2-3.pdf    . Accessed 12 Mar 2019."},{"key":"637_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/psychiatry.IndianJPsychiatry_37_17","volume":"59","author":"R Rao","year":"2017","unstructured":"Rao R. The journey of opioid substitution therapy in India: achievements and challenges. Indian J Psychiatry. 2017;59:39\u201345.","journal-title":"Indian J Psychiatry."},{"key":"637_CR39","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s11920-010-0135-5","volume":"12","author":"E Krupitsky","year":"2010","unstructured":"Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep. 2010;12:448\u201353.","journal-title":"Curr Psychiatry Rep"},{"key":"637_CR40","doi-asserted-by":"publisher","first-page":"157s","DOI":"10.1016\/S0924-9338(97)80446-4","volume":"12","author":"M Auriacombe","year":"1997","unstructured":"Auriacombe M, Franques P, Martin C, Lafitte C, Afflelou S, Bertorelle V, et al. Follow-up of a cohort of opioid dependent subjects in methadone and buprenorphine maintenance treatment: impact on quality of life. Eur Psychiatry. 1997;12:157s.","journal-title":"Eur Psychiatry."},{"key":"637_CR41","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/978-88-470-5322-9_21","volume-title":"Textbook of addiction treatment: international perspectives","author":"M Fatseas","year":"2015","unstructured":"Fatseas M, Dubernet J, Daoulouede JP, Auriacombe M. Buprenorphine in the treatment of opioid addiction: the French experience. In: el-Guebaly N, Carr\u00e0 G, Galanter M, editors. Textbook of addiction treatment: international perspectives. Springer: Milan; 2015. p. 501\u201310."},{"issue":"4","key":"637_CR42","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1370\/afm.2098","volume":"15","author":"J Dupouy","year":"2017","unstructured":"Dupouy J, Palmaro A, Fats\u00e9as M, Auriacombe M, Micallef J, Oustric S, et al. Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: a 7-year cohort study. Ann Family Med. 2017;15(4):355\u20138.","journal-title":"Ann Family Med."},{"key":"637_CR43","unstructured":"PCSS. Discover the rewards of treating patients with opioid use disorders. 2019. \n                    https:\/\/pcssnow.org\n                    \n                  . Accessed 18 Apr 2019."},{"issue":"3","key":"637_CR44","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/00952990.2011.653426","volume":"38","author":"SC Sigmon","year":"2012","unstructured":"Sigmon SC, Bisaga A, Nunes EV, O\u2019Connor PG, Kosten T, Woody G. Opioid medically supervised withdrawal and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse. 2012;38(3):187\u201399.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"2","key":"637_CR45","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1360-0443.2008.02455.x","volume":"104","author":"W Ling","year":"2009","unstructured":"Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, et al. Buprenorphine tapering schedule and illicit opioid use. Addiction. 2009;104(2):256\u201365.","journal-title":"Addiction"},{"issue":"8","key":"637_CR46","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/j.1360-0443.2005.01154.x","volume":"100","author":"W Ling","year":"2005","unstructured":"Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, et al. Multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid, medically supervised withdrawal: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005;100(8):1090\u2013100.","journal-title":"Addiction"},{"key":"637_CR47","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","volume":"150","author":"RD Weiss","year":"2015","unstructured":"Weiss RD, Potter JS, Griffin ML, Provost SE, Fitzmaurice GM, McDermott KA, et al. Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study. Drug Alcohol Depend. 2015;150:112\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"637_CR48","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","volume":"68","author":"RD Weiss","year":"2011","unstructured":"Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238\u201346.","journal-title":"Arch Gen Psychiatry"},{"issue":"1\u20132","key":"637_CR49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.drugalcdep.2009.11.008","volume":"108","author":"E Ravndal","year":"2010","unstructured":"Ravndal E, Amundsen EJ. Mortality among drug users after discharge from inpatient treatment: an 8-year prospective study. Drug Alcohol Depend. 2010;108(1\u20132):65\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"7129","key":"637_CR50","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/bmj.316.7129.426","volume":"316","author":"SR Seaman","year":"1998","unstructured":"Seaman SR, Brettle RP, Gore SM. Mortality from overdose among injecting drug users recently released from prison: database linkage study. BMJ. 1998;316(7129):426\u20138.","journal-title":"BMJ"},{"issue":"2","key":"637_CR51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMsa064115","volume":"356","author":"IA Binswanger","year":"2007","unstructured":"Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison: a high risk of death for former inmates. N Engl J Med. 2007;356(2):157\u201365.","journal-title":"N Engl J Med"},{"issue":"2","key":"637_CR52","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1046\/j.1360-0443.2003.00264.x","volume":"98","author":"SM Bird","year":"2003","unstructured":"Bird SM, Hutchinson SJ. Male drugs-related deaths in the fortnight after release from prison: scotland, 1996\u201399. Addiction. 2003;98(2):185\u201390.","journal-title":"Addiction"},{"issue":"6","key":"637_CR53","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/0024-3205(88)90454-7","volume":"42","author":"TR Kosten","year":"1988","unstructured":"Kosten TR, Kleber HD. Buprenorphine medically supervised withdrawal from opioid dependence: a pilot study. Life Sci. 1988;42(6):635\u201341.","journal-title":"Life Sci"},{"issue":"5","key":"637_CR54","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1176\/appi.ajp.2016.16050548","volume":"174","author":"M Sullivan","year":"2017","unstructured":"Sullivan M, Bisaga A, Pavlicova M, Choi CJ, Mishlen K, Carpenter KM, et al. Long-acting injectable naltrexone induction: a randomized trial of outpatient opioid medically supervised withdrawal with naltrexone versus buprenorphine. Am J Psychiatry. 2017;174(5):459\u201367.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"637_CR55","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"YI Hser","year":"2014","unstructured":"Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79\u201387.","journal-title":"Addiction"},{"issue":"4","key":"637_CR56","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/add.13238","volume":"111","author":"YI Hser","year":"2016","unstructured":"Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, et al. Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial. Addiction. 2016;111(4):695\u2013705.","journal-title":"Addiction"},{"issue":"9776","key":"637_CR57","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","volume":"377","author":"E Krupitsky","year":"2011","unstructured":"Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506\u201313.","journal-title":"Lancet"},{"issue":"13","key":"637_CR58","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","volume":"374","author":"JD Lee","year":"2016","unstructured":"Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374(13):1232\u201342.","journal-title":"N Engl J Med"},{"issue":"10118","key":"637_CR59","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","volume":"391","author":"JD Lee","year":"2018","unstructured":"Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309\u201318.","journal-title":"Lancet"},{"issue":"5","key":"637_CR60","doi-asserted-by":"publisher","first-page":"665","DOI":"10.4103\/0253-7176.217027","volume":"39","author":"S Das","year":"2017","unstructured":"Das S, Sah D, Nandi S, Das P. Opioid withdrawal presenting as delirium and role of buprenorphine: a case series. Indian J Psychol Med. 2017;39(5):665.","journal-title":"Indian J Psychol Med."},{"issue":"5","key":"637_CR61","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/ADM.0000000000000059","volume":"8","author":"JD Lee","year":"2014","unstructured":"Lee JD, Vocci F, Fiellin DA. Unobserved \u201chome\u201d induction onto buprenorphine. J Addict Med. 2014;8(5):299\u2013308.","journal-title":"J Addict Med."},{"key":"637_CR62","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jsat.2018.01.005","volume":"86","author":"SR Kenney","year":"2018","unstructured":"Kenney SR, Anderson BJ, Conti MT, Bailey GL, Stein MD. Expected and actual fentanyl exposure among persons seeking opioid withdrawal management. J Subst Abuse Treat. 2018;86:65\u20139.","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"637_CR63","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1176\/appi.ajp.2016.16070792","volume":"174","author":"KM Carroll","year":"2016","unstructured":"Carroll KM, Weiss RD. The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am J Psychiatry. 2016;174(8):738\u201347.","journal-title":"Am J Psychiatry."},{"issue":"4","key":"637_CR64","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jsat.2004.03.002","volume":"26","author":"M Galanter","year":"2004","unstructured":"Galanter M, Dermatis H, Glickman L, Maslansky R, Sellers MB, Neumann E, et al. Network therapy: decreased secondary opioid use during buprenorphine maintenance. J Subst Abuse Treat. 2004;26(4):313\u20138.","journal-title":"J Subst Abuse Treat"},{"issue":"13 Suppl. 1","key":"637_CR65","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1080\/10550490490440780","volume":"1","author":"M Auriacombe","year":"2004","unstructured":"Auriacombe M, Fats\u00e9as M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. Am J Addict. 2004;1(13 Suppl. 1):S17\u201328.","journal-title":"Am J Addict."},{"issue":"1","key":"637_CR66","doi-asserted-by":"publisher","first-page":"e20173652","DOI":"10.1542\/peds.2017-3652","volume":"142","author":"S Post","year":"2018","unstructured":"Post S, Spiller HA, Casavant MJ, Chounthirath T, Smith GA. Buprenorphine exposures among children and adolescents reported to US poison control centers. Pediatrics. 2018;142(1):e20173652.","journal-title":"Pediatrics"},{"issue":"1\u20132","key":"637_CR67","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","volume":"128","author":"AJ Saxon","year":"2013","unstructured":"Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, et al. Buprenorphine\/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013;128(1\u20132):71\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"637_CR68","doi-asserted-by":"publisher","first-page":"374.e1","DOI":"10.1016\/j.ajog.2016.03.015","volume":"215","author":"J Bell","year":"2016","unstructured":"Bell J, Towers CV, Hennessy MD, Heitzman C, Smith B, Chattin K. Medically supervised withdrawal from opiate drugs during pregnancy. Am J Obstet Gynecol. 2016;215(3):374.e1\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"24","key":"637_CR69","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","volume":"363","author":"HE Jones","year":"2010","unstructured":"Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320\u201331.","journal-title":"N Engl J Med"},{"issue":"12","key":"637_CR70","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1111\/add.13462","volume":"111","author":"BK Zedler","year":"2016","unstructured":"Zedler BK, Mann AL, Kim MM, Amick HR, Joyce AR, Murrelle EL, et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction. 2016;111(12):2115\u201328.","journal-title":"Addiction"},{"key":"637_CR71","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2018.5044","author":"T Disher","year":"2019","unstructured":"Disher T, Gullickson C, Singh B, Cameron C, Boulos L, Beaubien L, et al. Pharmacological treatments for neonatal abstinence syndrome: a systematic review and network meta-analysis. JAMA Pediatr. 2019. \n                    https:\/\/doi.org\/10.1001\/jamapediatrics.2018.5044\n                    \n                  .","journal-title":"JAMA Pediatr."},{"key":"637_CR72","unstructured":"BusinessWire. Amneal Pharmaceuticals received FDA approval for generic Suboxone\u00ae. 2019. \n                    https:\/\/www.businesswire.com\/news\/home\/20130225005607\/en\/Amneal-Pharmaceuticals-Receives-FDA-Approval-Generic-Suboxone%C2%AE\n                    \n                  . Accessed 18 Apr 2019."},{"issue":"12","key":"637_CR73","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1111\/add.12315","volume":"108","author":"RN Rosenthal","year":"2013","unstructured":"Rosenthal RN, Ling W, Casadonte P, Vocci F, Bailey GL, Kampman K, et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine\/naloxone. Addiction. 2013;108(12):2141\u20139.","journal-title":"Addiction"},{"issue":"3","key":"637_CR74","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1001\/jama.2016.9382","volume":"316","author":"RN Rosenthal","year":"2016","unstructured":"Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial. JAMA. 2016;316(3):282\u201390.","journal-title":"JAMA"},{"key":"637_CR75","unstructured":"Indivior United Kingdom. 2019. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209819s000lbl.pdf\n                    \n                  . Accessed 13 Mar 2019."},{"issue":"1","key":"637_CR76","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/JCP.0000000000000434","volume":"36","author":"AF Nasser","year":"2016","unstructured":"Nasser AF, Greenwald MK, Vince B, Fudala PJ, Twumasi-Ankrah P, Liu Y, et al. Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder. J Clin Psychopharmacol. 2016;36(1):18\u201326.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"637_CR77","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","volume":"178","author":"MR Lofwall","year":"2018","unstructured":"Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018;178(6):764\u201373.","journal-title":"JAMA Intern Med."},{"issue":"9","key":"637_CR78","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/jamapsychiatry.2017.1874","volume":"74","author":"SL Walsh","year":"2017","unstructured":"Walsh SL, Comer SD, Lofwall MR, Vince B, Levy-Cooperman N, Kelsh D, et al. Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74(9):894\u2013902.","journal-title":"JAMA Psychiatry."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00637-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-019-00637-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00637-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T23:06:03Z","timestamp":1589670363000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-019-00637-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,6]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["637"],"URL":"https:\/\/doi.org\/10.1007\/s40263-019-00637-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,6]]},"assertion":[{"value":"6 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Matisyahu Shulman and Jonathan M. Wai were funded by the National Institute on Drug Abuse Grant T32 DA007294. Edward V. Nunes was funded by the National Institute on Drug Abuse Grant K24 DA022412 (PI: Nunes). The authors alone are responsible for the content and writing of this article. Manuscript preparation and the decision to submit the manuscript for publication were the sole responsibilities of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Edward V. Nunes has served as an investigator on clinical trials for which Reckitt Benckiser Inc. supplied Suboxone, and for which Alkermes, Inc. supplied Vivitrol for study medication, and has served as a consultant without compensation on advisory boards to Alkermes, Inc. Matisyahu Shulman and Jonathan M. Wai have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}